CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced Dr. Laurence Corash, the Company’s co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by AABB’s National Blood Foundation.
The award, which was created in 2002, honors Dale A. Smith, a long-time Baxter Health executive who was responsible for establishing the Fenwal Division. The award is presented to individuals or organizations in recognition of groundbreaking work in utilizing technology for innovation in transfusion medicine or cellular therapies. The 2018 award is in acknowledgement of Dr. Corash’s role in developing pathogen reduction technology to prevent transfusion-transmitted infection and other complications of blood transfusion.
“I am honored to be selected as the 2018 award recipient,” said Dr. Laurence Corash. “My endeavors would not have been possible had it not been for the tireless efforts by Cerus’ employees and research collaborations with numerous clinicians and scientists in the US, Europe, and the Middle East. It is especially gratifying to see this technology move from the research laboratory to routine use in over 200 blood centers. Since introduction of this technology into routine use, blood centers have used INTERCEPT Blood System sets to produce more than 5 million pathogen-reduced blood components which have improved patient safety meaningfully.”
“This award is particularly meaningful because Dale Smith was a mentor to me,” continued Corash. “When I co-founded Cerus to develop pathogen-reduction technology, we formed a partnership with Baxter and Dale joined our Board of Directors.”
Corash will be presented the Dale A. Smith Memorial Award during the 2018 Annual AABB meeting which is being held in Boston between October 13th and 16th.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.